Safety and Immunogenicity of Live Viral Vaccines in a Multicenter Cohort of Pediatric Transplant Recipients
JAMA Network Open · 59 authors, 22 centres
AI SUMMARY
FIDELITY 100%
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This was a multicenter cohort study of 281 pediatric liver and kidney transplant recipients from 18 US transplant centers.
Full summary
536 CHARS
This was a multicenter cohort study of 281 pediatric liver and kidney transplant recipients from 18 US transplant centers. The primary outcome was the development of seroprotective antibodies following vaccination. Results showed no serious adverse events were observed, with 72% achieving varicella seroprotection, 86% measles, 83% mumps, and 99% rubella. The findings suggest live vaccination can be a safe and immunogenic intervention for select pediatric transplant recipients, potentially allowing for broader eligibility criteria.